
RADX
Healthcare · Biotechnology · $11.9M market cap
$0.7600-0.03 (-3.8%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Feb 26, 2026 | Time not confirmed | — | 0.00 | — |
| Dec 3, 2025 | Time not confirmed | — | -2.10 | — |
| Sep 16, 2025 | Time not confirmed | — | -0.01 | — |
| May 28, 2025 | Time not confirmed | — | -1.96 | — |
| Feb 28, 2025 | Time not confirmed | — | -0.01 | — |
Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast…